科研之友
微信
新浪微博
Facebook
分享链接
摘要
Introduction: Thymosin alpha 1 (T alpha 1) is a peptidic biological response modifier, which plays a significant role in activating and regulating various cells of the immune system. For the above-mentioned activities it is expected to exert a clinical benefit in the treatment of diseases where the immune system is altered. Areas covered: Several clinical trials have been carried out with T alpha 1 for treatment or prevention of many different infectious diseases such as hepatitis B and C, sepsis and Aspergillosis in bone marrow-transplanted patients. Data available on the use of T alpha 1 in infectious disease as well as a vaccine enhancer will be reviewed to possibly generate new working hypothesis. Expert opinion: T alpha 1 has been widely used in thousands of patients. Nevertheless, there are some issues that have not yet been properly addressed (i.e., dose, schedule, combination treatments, end-points to be evaluated in clinical trials). In the most recent clinical trials T alpha 1 has been used at higher doses than those commonly used in the past showing a direct proportionality between the dose and the effect. The safety profile of T alpha 1 is excellent and it is virtually devoid of toxicity.
- 出版日期2015-7
